Vyleesi and NSAIDs (Ibuprofen, Naproxen): What Women Need to Know About This Drug Interaction

What Is Bremelanotide (Vyleesi) and Who Is It For?

Vyleesi is the only FDA-approved melanocortin receptor agonist indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin-4 (MC4R) and, to a lesser extent, melanocortin-1 receptors in the central nervous system, which increases sexual desire independent of hormonal manipulation. You inject 1.75 mg subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity, no more than once in any 24-hour window.

HSDD affects an estimated 10% of premenopausal women in the United States, making it one of the most common female sexual dysfunctions. Because HSDD peaks in reproductive-age and perimenopausal women, understanding which medications can safely accompany Vyleesi matters in daily clinical life.

What NSAIDs Are We Talking About?

NSAIDs encompass a large class. The ones most relevant here are:

• Ibuprofen (Advil, Motrin): 200-800 mg per dose, typical OTC use 200-400 mg every 4-6 hours
• Naproxen (Aleve, Naprosyn): 220-500 mg per dose, OTC use 220 mg every 8-12 hours
• Other common agents: celecoxib, meloxicam, diclofenac, indomethacin

Women use NSAIDs more frequently than men, partly because of dysmenorrhea, endometriosis pain, fibromyalgia, and musculoskeletal conditions tied to the hormonal cycle. A woman managing painful periods might reach for ibuprofen on the same evening she plans to use Vyleesi. That specific scenario deserves a clear answer.

The Pharmacokinetics: Where the Interaction Does (and Does Not) Exist

There is no clinically meaningful pharmacokinetic drug-drug interaction between bremelanotide and standard NSAIDs. Here is why.

Bremelanotide's Metabolic Pathway

Bremelanotide is metabolized primarily by hydrolysis of amide bonds, not by cytochrome P450 enzymes. Its half-life is approximately 2.7 hours. Because CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are not meaningfully involved in its clearance, drugs that inhibit or induce those enzymes do not alter bremelanotide plasma concentrations in a clinically significant way.

P-glycoprotein (P-gp) transport also plays a negligible role in bremelanotide disposition, so P-gp inhibitors like ibuprofen at high doses are unlikely to matter for drug levels.

NSAIDs' Metabolic Pathway

Ibuprofen is metabolized by CYP2C9 and CYP2C8. Naproxen is metabolized primarily by CYP1A2 and CYP2C9. Neither of these pathways overlaps with bremelanotide's hydrolytic metabolism. The two drugs are processed through entirely separate enzymatic systems, which is why the FDA label for Vyleesi does not list NSAIDs among its drug interactions.

The bottom line on pharmacokinetics: combining Vyleesi with ibuprofen or naproxen will not meaningfully change the blood concentration of either drug through metabolic mechanisms.

The Real Issue: Pharmacodynamic Overlap

Even without a pharmacokinetic clash, two drugs can produce additive physiologic effects when their end-organ actions converge. That is the case here.

Blood Pressure Elevation

Bremelanotide causes a transient increase in mean arterial pressure (MAP) of approximately 2-4 mmHg, peaking around 12 minutes post-injection and resolving within 12 hours for most women. This is why Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

Regular NSAID use raises systolic blood pressure by an average of 3-5 mmHg, primarily through inhibition of renal prostaglandins that normally promote natriuresis. Even a single dose of ibuprofen may blunt the vasodilatory prostaglandin response for several hours. If you are already at the higher end of normal blood pressure, combining a transient pressor effect from Vyleesi with the renal sodium-retaining effect of an NSAID on the same evening could push MAP into a range that causes symptoms: flushing, headache, or palpitations.

Renal Prostaglandin Suppression

The kidneys rely on prostaglandins (particularly PGE2 and PGI2) to maintain glomerular perfusion under conditions of reduced renal blood flow. NSAIDs inhibit COX-1 and COX-2, suppressing renal prostaglandin synthesis and reducing glomerular filtration rate, particularly in women who are volume-depleted, have pre-existing renal insufficiency, or take renin-angiotensin system (RAS) blockers.

Bremelanotide does not directly inhibit renal prostaglandins, but its transient vasopressor effect means the renal vasculature is momentarily under higher afterload. In a healthy, well-hydrated woman with normal renal function, this is unlikely to matter for a single co-administration. In a woman with stage 2-3 CKD, a history of recurrent UTIs causing renal scarring, or a tendency to skip fluids, the combined renal stress is worth considering.

Gastrointestinal Effects

Bremelanotide's most common side effects include nausea (40%), flushing (20%), and headache (11%). NSAIDs independently cause gastric mucosal injury by inhibiting prostaglandin-mediated mucus production. For most women, the GI interaction is not additive in a dangerous pharmacologic sense because the mechanisms differ (central nausea from MC4R activation vs. Local GI mucosal injury from COX inhibition). The practical concern is experiential: nausea from Vyleesi, compounded by NSAID-induced GI irritation, may make you feel significantly worse on the same evening, particularly if you have a history of NSAID-sensitive gastritis or took the NSAID without food.

A practical decision framework for same-day use:

| Scenario | Risk Level | Suggested Approach | |---|---|---| | Healthy premenopausal woman, normal BP, occasional NSAID use | Low | Single OTC NSAID dose is likely acceptable; stay hydrated | | Woman with BP at the high-normal range (120-129/<80) | Moderate | Prefer acetaminophen instead of NSAID on Vyleesi days | | Woman with stage 1-2 hypertension on antihypertensives | High | Avoid NSAIDs on Vyleesi days; Vyleesi may already be contraindicated | | Woman with CKD stage 2-3 or history of NSAID-induced AKI | High | Avoid NSAIDs; discuss alternatives with your prescriber | | Perimenopausal woman with new cardiovascular risk factors | Moderate-High | Reassess both agents; acetaminophen is preferred NSAID alternative |

Life Stage Considerations

Reproductive Years (Ages 18-40)

This is the labeled population for Vyleesi. Women in this group are most likely to be using NSAIDs for dysmenorrhea or endometriosis. If your period pain brings you to ibuprofen or naproxen regularly, consider timing: Vyleesi is used on demand, so scheduling it on a day when you are not also treating heavy period pain reduces the chance of additive nausea or BP effects. For endometriosis specifically, hormonal suppression therapies and pelvic floor physical therapy may reduce NSAID dependence, giving you more flexibility.

Trying to Conceive

Vyleesi is contraindicated in pregnancy and must be discontinued before attempting conception. If you are actively trying to conceive, Vyleesi should not be in use. NSAIDs also carry their own reproductive concerns: NSAID use around the time of ovulation may impair follicle rupture, a phenomenon sometimes called "luteinized unruptured follicle syndrome," particularly with regular high-dose use. Women in the TTC phase should discuss both drugs with their OB-GYN or reproductive endocrinologist.

Perimenopause

Vyleesi is not FDA-approved for postmenopausal women, but perimenopausal women are within the labeled premenopausal population if they have not yet had 12 consecutive months without a period. Cardiovascular risk rises meaningfully during perimenopause, and both Vyleesi's BP effect and NSAID-related sodium retention become more clinically significant against that background. Women in perimenopause using Vyleesi should have their blood pressure checked more regularly and should minimize chronic NSAID use, favoring acetaminophen where possible.

Postmenopause

Vyleesi is not indicated in this life stage. Postmenopausal HSDD has different neurobiological underpinning, and the drug has not been studied in this group. If you are postmenopausal and experiencing low sexual desire, the conversation with your clinician should center on hormone therapy, ospemifene, or other evidence-based options, not bremelanotide.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age and using Vyleesi.

Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal studies showed fetal harm at doses relevant to human exposure, and there are no adequate, well-controlled studies in pregnant women. The Vyleesi FDA label states the drug should not be used during pregnancy. Because Vyleesi is used on demand and sexual activity can result in pregnancy, women who are not using reliable contraception should resolve that before starting this medication.

NSAIDs carry their own pregnancy warnings. Ibuprofen and naproxen are contraindicated at 20 weeks gestation or later due to the risk of fetal renal dysfunction, oligohydramnios, and premature closure of the ductus arteriosus. Before 20 weeks, NSAIDs should be used only when necessary and at the lowest effective dose.

If you become pregnant while using Vyleesi, stop the medication immediately and contact your OB-GYN.

Lactation

There are no human data on bremelanotide transfer into breast milk. Given the drug's peptide structure and relatively short half-life of approximately 2.7 hours, milk transfer is theoretically limited but not characterized. The FDA label advises against use during breastfeeding. The most conservative approach is to pump and discard for 24 hours after a Vyleesi dose if breastfeeding a newborn, though this has not been formally evaluated in clinical studies.

NSAIDs in lactation have a more established profile. Ibuprofen is considered compatible with breastfeeding by LactMed, given its low milk transfer and short half-life. Naproxen is used with more caution given its longer half-life (12-17 hours) and limited infant data.

Contraception Requirements

Because Vyleesi is contraindicated in pregnancy and used on demand near sexual activity, reliable contraception is not a labeled requirement but is strongly implied by the contraindication. ACOG recommends that women using teratogenic or fetotoxic medications have a contraceptive plan documented at the time of prescribing. Discuss your contraceptive method with your prescriber when starting Vyleesi.

Who This Is Right For, and Who Should Reconsider

Good candidates for Vyleesi with occasional NSAID use

• Premenopausal women with confirmed HSDD, normal blood pressure (<120/80), and good renal function who occasionally take an OTC NSAID dose for acute pain
• Women who can separate Vyleesi and NSAID use by at least 12-24 hours on most occasions

Women who should pause and discuss with their clinician

• Women with blood pressure consistently 130/80 or higher
• Women with any stage of chronic kidney disease
• Women on daily or high-dose NSAIDs for a chronic condition (rheumatoid arthritis, ankylosing spondylitis, endometriosis)
• Women with a history of cardiovascular disease, which already contraindicates Vyleesi

Conditions that make this interaction more relevant

NSAID use is very common in women managing endometriosis, PCOS-related pelvic pain, and perimenopausal musculoskeletal complaints. Each of these conditions warrants an individualized conversation rather than a blanket rule.

Safer Pain Relief Alternatives on Vyleesi Days

If you need pain relief on a day you plan to use Vyleesi, acetaminophen (Tylenol) is the preferred option. It does not inhibit COX enzymes, does not raise blood pressure, and has no known pharmacodynamic interaction with bremelanotide. Standard dosing of 500-1000 mg every 6-8 hours (not exceeding 3,000-4,000 mg per 24 hours depending on liver health) is appropriate for most women.

For menstrual pain specifically, transcutaneous electrical nerve stimulation (TENS), heat application, and magnesium supplementation have evidence for dysmenorrhea and carry no drug interaction risk with Vyleesi.

Evidence Gaps and What Is Extrapolated

Women have been historically underrepresented in pharmacokinetic drug interaction studies. The data on Vyleesi's interaction profile comes primarily from the FDA-submitted clinical pharmacology package for the 2019 approval, and formal NSAID interaction studies were not conducted. The conclusions above about pharmacodynamic overlap are based on known mechanisms of each drug, not on a dedicated clinical trial measuring outcomes when both are co-administered.

This is an honest limitation. If you are a woman with multiple comorbidities or are on several medications, a clinical pharmacist consultation is a reasonable step, not just a boilerplate suggestion.

As the Vyleesi label states directly: "No clinical drug interaction studies have been performed with bremelanotide." The absence of a listed interaction is not the same as confirmed safety in all populations.

Monitoring and Counseling Points

If you and your clinician decide occasional NSAID use alongside Vyleesi is acceptable for your situation, here is what to track:

• Blood pressure: Check your BP at home on any day you use both agents. A reading above 160/100 within 12 hours of Vyleesi use should prompt you to contact your prescriber.
• Symptoms to report: Severe headache, chest pain, palpitations, or significant reduction in urine output after co-administration warrant prompt evaluation.
• Hydration: Drink at least 500 mL of water in the hours surrounding both agents to support renal prostaglandin reserves.
• Chronic NSAID users: If you take an NSAID daily or near-daily, discuss with your prescriber whether a COX-2-selective inhibitor or a non-NSAID alternative reduces your overall cardiovascular and renal risk before adding Vyleesi.

A 2022 analysis published in Hypertension found that NSAID use was associated with a meaningful increase in the risk of incident hypertension, particularly with ibuprofen at doses of 1200 mg/day or more. For a woman already experiencing Vyleesi-related MAP increases, chronic ibuprofen at that level is a combination worth avoiding.